The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …

To face the COVID-19 outbreak, a wide range of non-pharmaceutical interventions (NPIs)
aimed at limiting the spread of the virus in communities, such as mask-wearing, hand …

We tracked the effective reproduction number (R t) of the predominant severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron BF. 7 in Beijing in …

In late 2022, China transitioned from a strict 'zero-COVID'policy to rapidly abandoning nearly
all interventions and data reporting. This raised great concern about the presumably-rapid …

A safe and effective vaccine with long-term protection against SARS-CoV-2 variants of
concern (VOCs) is a global health priority. Here, we develop lipid nanoparticles (LNPs) to …

A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India …

A critical step in the process for preventing and identifying emergencies relating to health,
safety, and welfare is the testing and quick diagnosis of microbial pathogens. Due to the fast …

As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to
develop intranasal, broadly protective vaccines. Here, we developed highly efficacious …

The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high
transmissibility, immune evasion, and reduced severity when compared to the earlier …

While first-generation, spike (S)-based COVID-19 vaccines were effective against early
SARS-CoV-2 strains, the rapid evolution of novel Omicron subvariants have substantially …